Johnson & Johnson - DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer

About this update from Johnson & Johnson

RAYNHAM - DePuy Synthes , a global leader in orthopaedic technologies and solutions, announced the appointment of Christina Zamarro as Chief Financial Officer, DePuy Synthes , effective July 13, 2026 . Zamarro brings over 25 years of financial leadership experience serving in multitude of roles across treasury, investor relations, FP&A and accounting. She joins DePuy Synthes from the Goodyear Tire & Rubber Company , a global manufacturer, where she most recently served as the Chief Financial Officer. 'I am excited to welcome Christina to the DePuy Synthes team,' said Namal Nawana , Worldwide President, DePuy Synthes . 'With more than two decades of financial leadership, she brings deep experience managing global and complex transformation programs. I look forward to partnering closely with Christina as we continue building on our momentum.' Throughout her career, Christina has advanced through leadership roles spanning treasury, investor relations, and FP&A. She held responsibility for capital markets, liquidity, and financial risk management globally before leading investor relations and later enterprise financial planning and performance management. Christina earned an MBA from Vanderbilt University and a BA in Economics from Ohio Wesleyan University . She also serves on the board of L3Harris Technologies , where she is a member of the Audit Committee. About DePuy Synthes DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement to the millions of patients we serve. Our solutions-including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine-alongside the VELYS Digital Surgery portfolio, are designed to support improved patient care and deliver clinical and economic value to healthcare systems worldwide. Building on a legacy of product innovation and industry firsts, we continue to shape the orthopaedic landscape through advancements in medical technologies and digital surgery across the continuum of care to Keep People Moving today and tomorrow. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms and trends toward health care cost containment. Contact: Lindsey Diaz-MacInnis Email: [email protected] Sandra Easton Email: [email protected] (C) 2026 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Johnson & Johnson